Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 61

FDA clears AstraZeneca's Imfinzi-Padcev combo for muscle-invasive bladder cancer

AstraZeneca won FDA approval for its Imfinzi and Padcev combination in muscle-invasive bladder cancer, aimed at patients who can't tolerate or refuse cisplatin chemotherapy. The priority-review green light rests on the VOLGA trial, where the perioperative regimen cut the risk of progression, recurrence or death by 49%.

By the Paparazzi desk November 16, 2026 · 2:36 AM · yahoo.com · 1 view
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: yahoo.com.
  • The source published it on Nov 16, 2026 at 2:36 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The US Food and Drug Administration approved AstraZeneca's Imfinzi (durvalumab) alongside Padcev (enfortumab vedotin) for adults with muscle-invasive bladder cancer who cannot receive or have turned down cisplatin-based chemotherapy. The clearance came under priority review and covers a regimen built with Astellas Pharma and Pfizer's Padcev.

The schedule runs in two stages: neoadjuvant treatment before radical cystectomy, then single-agent Imfinzi as adjuvant therapy afterward. It leans on the multi-centre VOLGA Phase III study, published in The New England Journal of Medicine and presented at the 2026 European Society for Medical Oncology Congress.

Sponsored

In the 695-patient trial, the perioperative regimen reduced the risk of disease progression, recurrence, omitted surgery or death by 49% versus radical cystectomy with or without approved adjuvant treatment. Two-year event-free survival landed at an estimated 64%, against 45% in the control arm, where median event-free survival was 12.1 months. Overall survival showed a 42% drop in the risk of death, with two-year rates of 78% versus 69%.

Grade 3 and 4 adverse events from any cause hit 64% of patients on the combination, compared with 44% in the comparator arm. No new safety signals turned up, and patient-reported quality of life held steady after surgery.

Dave Fredrickson, executive vice president of AstraZeneca's oncology haematology business unit, said the approval offers a regimen that almost halved recurrence risk and cut death risk by 42% in VOLGA. He called it the company's third bladder cancer indication in two years, reinforcing Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.

Muscle-invasive tumours make up roughly a quarter of bladder cancer cases, with about 16,000 people in the US expected to receive treatment in 2026. Up to 50% of patients can't tolerate cisplatin because of impaired renal function or other comorbidities, leaving radical cystectomy as the long-standing standard despite frequent recurrences. AstraZeneca's May approval paired Imfinzi with Bacillus Calmette-Guérin for BCG-naïve, high-risk non-muscle-invasive cases, and filings based on the VOLGA trial remain under review in the European Union, Japan and other territories.

TopicsAstraZeneca · Imfinzi · Padcev · FDA · Astellas Pharma · Pfizer · Dave Fredrickson · VOLGA trial

Share

Source: yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 52 minutes ago · finance.yahoo.com · 0 views
    Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
  • Health & science 3 hours ago · casrai.org · 0 views
    FDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
  • Health & science 4 hours ago · nbcnews.com · Caught by @nina.anggraini29 · 0 views
    Measles Is Endemic Again as the U.S. Loses Its Elimination Status
  • Health & science 4 hours ago · aol.com · 1 view
    FDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.